Streetwise Reports (04/08/2024)
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
Streetwise Reports (04/03/2024)
This Canada-based health care technology firm is profitable and growing. Learn more about it here.
Streetwise Reports (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
Streetwise Reports (03/27/2024)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
Streetwise Reports (03/26/2024)
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector.